Abstracts tagged "cytokines"

Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 1487 • 2018 ACR/ARHP Annual Meeting
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Ottar Gadeholt¹, Erin Arnold², Corinne Gorman³, Tobias Mueller⁴ and William Arnold², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Orthopedics and Rheumatology of the North Shore, Skokie, IL, ³Orthopaedics & Rheumatology of the North Shore, Skokie, IL, ⁴Department of Bioinformatics, University of Wuerzburg, Wuerzburg, Germany
Background/Purpose: Multiple cytokines are assumed to be involved in RA pathogenesis. It has been hypothesized that ACPA-negative RA with wrist affection constitutes a separate entity.…
Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Joel M. Guthridge¹, Eliza Chakravarty¹, Hua Chen¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Stanford University, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…
Abstract Number: 137 • 2018 ACR/ARHP Annual Meeting
Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Ken Tsumiyama and Shunichi Shiozawa, Institute for Rheumatic Diseases, Nagahama, Japan
Background/Purpose: We have shown that repeated immunization with antigen induces systemic lupus erythematosus (SLE) in the mice otherwise not prone to spontaneous autoimmune diseases. We…
Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Michal Cesak⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Barbora Sumova^1,2, Olga Ruzickova^1,6, Herman F Mann^1,7, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Jiri Vencovsky^1,8, Radim Becvar^1,2 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
Abstract Number: 155 • 2018 ACR/ARHP Annual Meeting
Polyfunctional Synovial T-Cell Responses and Synovial Invasiveness Repressed By Blockade of Phosphodiesterase 4
Sarah M. Wade¹, Mary Canavan¹, Trudy McGarry¹, Siobhan C. Wade¹, Ronan Mullan², Douglas J. Veale³ and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Genetic and functional studies strongly support the role of T-cells in PsA pathophysiology. Effective targeting of T-cells requires a detailed understanding of their phenotypic…
Abstract Number: 1743 • 2018 ACR/ARHP Annual Meeting
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Anders Heiervang Tennøe¹, Håvard Fretheim², Oyvind Midtvedt², Torhild Garen², Thor Ueland³, Pål Aukrust², Arne K Andreassen², Einar Gude², Øyvind Molberg² and Anna-Maria Hoffmann-Vold², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Research Institute of Internal Medicine Research, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a feared complication in systemic sclerosis (SSc). Detection of PAH at a preclinical stage is important as early diagnosis…
Abstract Number: 809 • 2018 ACR/ARHP Annual Meeting
The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Henriette Didriksen¹, Håvard Fretheim¹, Vyacheslav Palchevskiy², Arne K Andreassen¹, Torhild Garen¹, Oyvind Midtvedt¹, Einar Gude¹, John A Belperio³, Øyvind Molberg¹ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is characterized by abnormalities in vascular pathways and lymphatic vessels with pulmonary hypertension as a major complication. Vascular endothelial growth factor…
Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting
A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Chris Buckley¹, Jesus A Simon Campos², Sergey Yakushin³, Vyacheslav Zhdan⁴, Katherine Davy⁵, David Inman⁶, Elena Fisheleva^7,8, Anubha Gupta⁸, Mark Layton⁹, Nina Mitchell^7,8, Jatin Patel¹⁰, Russell Williamson⁶ and Paul-Peter Tak¹¹, ¹University of Birmingham, Birmingham, United Kingdom, ²Hospital CEM/BIOCEM, Merida, Mexico, ³Ryazan Regional Clinical Cardiology Dispensary, Ryazan, Russian Federation, ⁴M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, ⁵Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Stockley Park, United Kingdom, ⁷Currently at Biomarin UK Ltd, London, United Kingdom, ⁸GlaxoSmithKline, Stevenage, United Kingdom, ⁹ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ¹⁰ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ¹¹University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…
Abstract Number: 842 • 2018 ACR/ARHP Annual Meeting
Interleukin 17 Receptor D (IL-17RD) Is Regulated By Pro-Inflammatory Cytokines and Plays a Role in the Development of Collagen-Induced Arthritis
M Molendijk¹, A Otten-Mus², P Asmawidjaja³, Dominique Baeten⁴ and Erik Lubberts⁵, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology and Clinical Immunology, AMC, Amsterdam, Netherlands, ⁵Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Interleukin-17 Receptor D (IL-17RD) otherwise known as similar expression of fibroblast growth factor genes (SEF) is often described as an inhibitor of multiple signaling…
Abstract Number: 2040 • 2018 ACR/ARHP Annual Meeting
Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.
Morten Aagaard Nielsen¹, Tue Wenzel Kragstrup², Kristian Stengaard-Pedersen³, Kim Hørslev-Petersen⁴, Merete Lund Hetland⁵, Mikkel Østergaard⁶, Peter Junker⁷, Malene Hvid⁸, Ulf Nilsson⁹, John Stegmayr¹⁰, Hakon Leffler¹¹ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Randers Regional Hospital, Randers, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁴King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, The DANBIO Registry, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁹Deptment of Chemistry, Center for analysis and Synthesis, Lund, Sweden, ¹⁰Department of Laboratory Medicine, Division of Microbiology, Immunology, and Glycobiology (MIG), Lund University, LUND, Sweden, ¹¹Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology - MIG, Lund University, LUND, Sweden
Background/Purpose: Galectin-3 (Gal-3) and the co-stimulatory T cell receptor and glycoprotein 4-1BB are both considered important in inflammation and immune responses. This had led to…
Abstract Number: 38 • 2017 ACR/ARHP Annual Meeting
Cytokine Production By CpG-Activated B Cells Require Glutaminolysis to Drive mTOR Activation, Aerobic Glycolysis and Mitochondrial Respiration
Matthew Cheung¹, Dongyue Huang¹, Emily Liu², Jennifer Ra² and Alfred Kim³, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²IM/Rheumatology, Washington University School of Medicine, Saint Louis, MO, ³IM/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: B cells contribute to disease pathophysiology through several mechanisms, including cytokine secretion. A wide variety of stimuli can activate B cells to produce cytokines…
Abstract Number: 1381 • 2017 ACR/ARHP Annual Meeting
Skeletal Muscle Cytokine and Myostatin Responses to High-Intensity Interval Training in Rheumatoid Arthritis Contrasted with Prediabetes Mellitus
Brian J. Andonian¹, David Bartlett², Virginia B. Kraus³, Janet Huebner², William E. Kraus⁴ and Kim M. Huffman⁵, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵School of Medicine, Division of Rheumatology, Immunology and Molecular Physiology and Durham VA Medical Center, Duke University, Durham, NC
Background/Purpose: Sarcopenic obesity and the associated risk of cardiovascular disease (CVD) and mortality in rheumatoid arthritis (RA) may be related to dysregulated skeletal muscle remodeling…
Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Tony Muchamuel¹, Janet Anderl², R Andrea Fan², Henry W. B. Johnson³, Christopher J Kirk⁴ and Eric Lowe², ¹Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].